Synthetic lethal approaches to breast cancer therapy
- 19 October 2010
- journal article
- review article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 7 (12) , 718-724
Abstract
The promise of personalized therapy for breast cancer is that therapeutic efficacy will be increased while toxic effects are reduced to a minimum. To achieve this goal, there is now an emphasis on the design of therapies that are based not only on the clinical manifestations of the disease, but also on the underlying molecular and cellular biology of cancer. However, identifying targets for personalized therapies in breast cancer is challenging. Here, we describe how biological concepts such as synthetic lethality and oncogene addiction can be used to identify new therapeutic targets and approaches. We discuss the current clinical developments in implementing synthetic lethality therapies, and highlight new ways in which this approach could be used to target specific subsets of breast cancer.Keywords
This publication has 83 references indexed in Scilit:
- Roles of small RNAs in tumor formationTrends in Molecular Medicine, 2010
- Signatures of mutation and selection in the cancer genomeNature, 2010
- A comprehensive catalogue of somatic mutations from a human cancer genomeNature, 2009
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Molecular Medicine, 2009
- Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53Nature Genetics, 2009
- Tenets of PTEN Tumor SuppressionCell, 2008
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008
- p53-Deficient Cells Rely on ATM- and ATR-Mediated Checkpoint Signaling through the p38MAPK/MK2 Pathway for Survival after DNA DamageCancer Cell, 2007
- The PARP superfamilyBioEssays, 2004
- Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2Nature Genetics, 1996